Cdk 4/6 Drug Target Activation Mapping Of Hr+/Her2-Metastatic Breast Cancer For Treatment Selection And Response Prediction.

Maysa M. Abu-Khalaf,Christos Hatzis,K. Alex Hodge,Frances Valdes,William M. Sikov,Monica M. Mita,Neelima Denduluri,Kris Awerkamp,Rita Murphy,Daniel Zelterman,Bryant Dunetz,Emanuel Petricoin,Mariaelena Pierobon

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 1|浏览34

暂无评分

摘要

e13029Background: Despite the fact that a number of CDK 4/6 inhibitors have become FDA approved as the main frontline therapy for HR+/HER2- metastatic breast cancer (MBC), there are no validated pr...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要